187 related articles for article (PubMed ID: 33138083)
1. Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma.
Rossitti HM; Dutta RK; Larsson C; Ghayee HK; Söderkvist P; Gimm O
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138083
[TBL] [Abstract][Full Text] [Related]
2. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
[TBL] [Abstract][Full Text] [Related]
3. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide.
Chatzikyriakou P; Brempou D; Quinn M; Fishbein L; Noberini R; Anastopoulos IN; Tufton N; Lim ES; Obholzer R; Hubbard JG; Moonim M; Bonaldi T; Nathanson KL; Izatt L; Oakey RJ
Clin Epigenetics; 2023 Dec; 15(1):196. PubMed ID: 38124114
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
[TBL] [Abstract][Full Text] [Related]
8. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
9. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
[TBL] [Abstract][Full Text] [Related]
11. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract][Full Text] [Related]
12. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
Crona J; Taïeb D; Pacak K
Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
[TBL] [Abstract][Full Text] [Related]
13. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
14. HRAS mutation prevalence and associated expression patterns in pheochromocytoma.
Stenman A; Welander J; Gustavsson I; Brunaud L; Bäckdahl M; Söderkvist P; Gimm O; Juhlin CC; Larsson C
Genes Chromosomes Cancer; 2016 May; 55(5):452-9. PubMed ID: 26773571
[TBL] [Abstract][Full Text] [Related]
15. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
Eisenhofer G; Pacak K; Huynh TT; Qin N; Bratslavsky G; Linehan WM; Mannelli M; Friberg P; Grebe SK; Timmers HJ; Bornstein SR; Lenders JW
Endocr Relat Cancer; 2011 Feb; 18(1):97-111. PubMed ID: 21051559
[TBL] [Abstract][Full Text] [Related]
16. MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.
Tomić TT; Olausson J; Rehammar A; Deland L; Muth A; Ejeskär K; Nilsson S; Kristiansson E; Wassén ON; Abel F
PLoS Genet; 2020 Jun; 16(6):e1008803. PubMed ID: 32511227
[TBL] [Abstract][Full Text] [Related]
17.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
Toledo RA; Qin Y; Cheng ZM; Gao Q; Iwata S; Silva GM; Prasad ML; Ocal IT; Rao S; Aronin N; Barontini M; Bruder J; Reddick RL; Chen Y; Aguiar RC; Dahia PL
Clin Cancer Res; 2016 May; 22(9):2301-10. PubMed ID: 26700204
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
20. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
